These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 2902861)

  • 1. Pharmacological profile of a new potent 5-hydroxytryptamine (5-HT2) alpha 1-receptor antagonist.
    Schröder G; Beckmann R; Gerbling KP; Loge O; Maass B; Müller B; Seidelmann D; Schneider HH; Schulz BG; Stürzebecher CS
    Arzneimittelforschung; 1988 Jun; 38(6):765-70. PubMed ID: 2902861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors.
    Van Nueten JM; Janssen PA; Van Beek J; Xhonneux R; Verbeuren TJ; Vanhoutte PM
    J Pharmacol Exp Ther; 1981 Jul; 218(1):217-30. PubMed ID: 6113280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LY215840, a potent 5-hydroxytryptamine (5-HT)2 receptor antagonist, blocks vascular and platelet 5-HT2 receptors and delays occlusion in a rabbit model of thrombosis.
    Cohen ML; Robertson DW; Bloomquist WE; Wilson HC
    J Pharmacol Exp Ther; 1992 Apr; 261(1):202-8. PubMed ID: 1560366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihypertensive properties of ketanserin (R 41 468).
    Vanhoutte PM; Van Nueten JM; Symoens J; Janssen PA
    Fed Proc; 1983 Feb; 42(2):182-5. PubMed ID: 6295821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-HT2-receptor antagonists: alpha 1- vs. 5-HT2-receptor blocking properties in blood vessels.
    Cohen ML; Schenck KW; Kurz KD
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S25-9. PubMed ID: 2459510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of the hypotensive effect of a novel phenylpiperazine derivative, SGB-1534: antagonism at alpha 1-adrenergic and 5-HT2 receptors.
    Aono J; Nabata H; Ishizuka N; Sakai K
    Arch Int Pharmacodyn Ther; 1985 Sep; 277(1):126-39. PubMed ID: 2865933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological profile of a new 5-hydroxytryptamine2 receptor antagonist, DV-7028.
    Shibano T; Tanaka T; Morishima Y; Yasuoka M; Watanabe K; Fujii F
    Arch Int Pharmacodyn Ther; 1992; 319():114-28. PubMed ID: 1285670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical and pharmacological properties of SR 46349B, a new potent and selective 5-hydroxytryptamine2 receptor antagonist.
    Rinaldi-Carmona M; Congy C; Santucci V; Simiand J; Gautret B; Neliat G; Labeeuw B; Le Fur G; Soubrie P; Breliere JC
    J Pharmacol Exp Ther; 1992 Aug; 262(2):759-68. PubMed ID: 1501121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine.
    Guarneri L; Angelico P; Ibba M; Poggesi E; Taddei C; Leonardi A; Testa R
    Arzneimittelforschung; 1996 Jan; 46(1):15-24. PubMed ID: 8821512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical pharmacology of a new serotonergic receptor antagonist, LY281067.
    Cohen ML; Fuller RW; Kurz KD; Parli CJ; Mason NR; Meyers DB; Smallwood JK; Toomey RE
    J Pharmacol Exp Ther; 1988 Jan; 244(1):106-12. PubMed ID: 3335993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist.
    Nishikibe M; Ohta H; Okada M; Ishikawa K; Hayama T; Fukuroda T; Noguchi K; Saito M; Kanoh T; Ozaki S; Kamei T; Hara K; William D; Kivlighn S; Krause S; Gabel R; Zingaro G; Nolan N; O'Brien J; Clayton F; Lynch J; Pettibone D; Siegl P
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1262-70. PubMed ID: 10336515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the non-peptide B2 antagonist FR173657 on kinin-induced smooth muscle contraction and relaxation, vasoconstriction and prostaglandin release.
    Griesbacher T; Sametz W; Legat FJ; Diethart S; Hammer S; Juan H
    Br J Pharmacol; 1997 Jun; 121(3):469-76. PubMed ID: 9179388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. APD791, 3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biology.
    Adams JW; Ramirez J; Shi Y; Thomsen W; Frazer J; Morgan M; Edwards JE; Chen W; Teegarden BR; Xiong Y; Al-Shamma H; Behan DP; Connolly DT
    J Pharmacol Exp Ther; 2009 Oct; 331(1):96-103. PubMed ID: 19628629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LY53857, a selective and potent serotonergic (5-HT2) receptor antagonist, does not lower blood pressure in the spontaneously hypertensive rat.
    Cohen ML; Fuller RW; Kurz KD
    J Pharmacol Exp Ther; 1983 Nov; 227(2):327-32. PubMed ID: 6313898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
    Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D
    Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypotensive and antiaggregative effects of eugenosedin-B with serotonin and alpha/beta-adrenoceptor antagonistic activities in rats and human platelets.
    Shen KP; Chu LW; Hsieh SL; An LM; Chen IJ; Wu BN
    J Cardiovasc Pharmacol; 2008 Feb; 51(2):154-61. PubMed ID: 18287883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AHR-16303B, a novel antagonist of 5-HT2 receptors and voltage-sensitive calcium channels.
    Barrett RJ; Appell KC; Kilpatrick BF; Proakis AG; Nolan JC; Walsh DA
    J Cardiovasc Pharmacol; 1991 Jan; 17(1):41-53. PubMed ID: 1708055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential inhibition of 5-hydroxytryptamine (5-HT) mediated contraction of rat thoracic aortae by phentolamine and tolazoline: correlation with inhibition of 5-HT binding and calcium ion.
    Curro FA; Greenberg S
    Methods Find Exp Clin Pharmacol; 1983; 5(2):107-20. PubMed ID: 6876942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on the pharmacology of the novel histamine H3 receptor agonist Sch 50971.
    Hey JA; Aslanian R; Bolser DC; Chapman RW; Egan RW; Rizzo CA; Shih NY; Fernandez X; McLeod RL; West R; Kreutner W
    Arzneimittelforschung; 1998 Sep; 48(9):881-8. PubMed ID: 9793613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular effects of CPU-23, a novel L-type calcium channel blocker with a unique molecular structure.
    Dong H; Earle ML; Jiang Y; Loutzenhiser KA; Triggle CR
    Br J Pharmacol; 1997 Dec; 122(7):1271-8. PubMed ID: 9421272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.